REFERENCES
  1. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20:669-77.
  2. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Available at: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Accessed in November, 2020.
  3. Falavigna M, Colpani V, Stein C, et al. Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology. Diretrizes para o tratamento farmacológico da COVID-19. Consenso da Associação de Medicina Intensiva Brasileira, da Sociedade Brasileira de Infectologia e da Sociedade Brasileira de Pneumologia e Tisiologia. Rev Bras Ter Intensiva.2020;32(2):166-196.
  4. Polanczyk CA, Rohsig V, Bastos GN, et al. Getting Ready for the Covid-19 Pandemic: Experience of a Brazilian Hospital. N Engl J Med . 2020.
  5. Wise J, Coombes R. Covid-19: The inside story of the RECOVERY trial.BMJ . 2020;370:m2670.
  6. Barda N, Riesel D, Akriv A, et al. Developing a COVID-19 mortality risk prediction model when individual-level data are not available.Nat Commun . 2020;11:4439.
  7. Zhao Z, Anne C, Wei H, et al. Prediction model and risk scores of ICU admission and mortality in COVID-19. PloS one . 2020;15,7: e0236618.
  8. WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.N Engl J Med. 2020;NEJMoa2023184.
  9. Simonovich VA, Burgos Pratx LD, Scibona P, et al. PlasmAr Study Group. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med. 2020:NEJMoa2031304.
  10. Fang X, Mei Q, Yang T, et al. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19. J Infect . 2020;81(1):147-178.
  11. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395(10225):683-684.
  12. World Health Organization. Corticosteroids for COVID-19 guideline. Available at:https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1. Accessed in December, 2020.
  13. De Backer D, Azoulay E, Vincent JL. Corticosteroids in severe COVID-19: a critical view of the evidence. Crit Care.2020;24:627.
  14. Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020;76(16):1815-1826.
  15. Tanriverdİ E, ÇÖrtÜk M, Yildirim BZ, et al. The use of hydroxychloroquine plus azithromycin and early hospital admission are beneficial in Covid-19 patients: Turkey experience with real-life data. Turk J Med Sci. 2020.
  16. Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Di s. 2020;97:396-403.
  17. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Coalition Covid-19 Brazil I Investigators. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med.2020;383(21):2041-2052.
  18. Self WH, Semler MW, Leither LM, et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020;e2022240.
  19. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020;323(24):2493–2502. doi:10.1001/jama.2020.8630
  20. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. Preprint. medRxiv. 2020;2020.04.16.20065920.
  21. Kalligeros M, Shehadeh F, Atalla E, et al. Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study. J Glob Antimicrob Resist . 2020;22:842-844.
  22. Lin SM, Liu KX, Lin ZH, Lin PH. Does high-flow nasal cannula oxygen improve outcome in acute hypoxemic respiratory failure? A systematic review and meta-analysis. Respir Med . 2017;131:58-64.
  23. Geng S, Mei Q, Zhu C, et al. High flow nasal cannula is a good treatment option for COVID-19. Heart Lung . 2020;49(5):444-445.
  24. Yamada T, Wakabayashi M, Yamaji T, et al. Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis. Clinica Chimica Acta; International Journal of Clinical Chemistry.2020;509:235-243.
  25. Huang HD, Jneid H, Aziz M, et al. Safety and Effectiveness of Hydroxychloroquine and Azithromycin Combination Therapy for Treatment of Hospitalized Patients with COVID-19: A Propensity-Matched Study.Cardiol Ther . 2020;9(2):523-534.
  26. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol . 2020;1;5(9):1036-1041.
  27. Chorin E, Wadhwani L, Magnani S, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm . 2020;17(9):1425-1433.
  28. Saleh M, Gabriels J, Chang D, et al. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. Circ Arrhythm Electrophysiol . 2020;13(6):e008662.